Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Volatile Organic Compounds in Cystic Fibrosis (VOCCF)

This study has been completed.
Information provided by (Responsible Party):
Chris Landon, Landon Pediatric Foundation Identifier:
First received: June 21, 2011
Last updated: August 12, 2014
Last verified: August 2014

This experiment is designed to test the effectiveness of a new electronic nose device, which allows a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of bacterial organisms in the lower respiratory tract. It consists of:

  • A breath collection apparatus for collection of volatile organic compounds in breath onto a sorbent trap and Tedlar bag, as well as for the collection of a separate sample of room air.
  • Analysis of the volatile organic compounds in breath and room air by short acoustic wave/gas chromatography.
  • Interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of lower respiratory tract colonization and infection.

This study will test the hypothesis that the investigators can identify the presence of Pseudomonas aeruginosa by sampling the "head space" above culture media of sputum provided by patients with cystic fibrosis. This study will test the additional hypothesis that the investigators can identify the presence of Pseudomonas aeruginosa by sampling exhaled breath from the patient providing the sputum.

Condition Intervention
Cystic Fibrosis
Pseudomonas Aeruginosa
Other: Cystic Fibrosis patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Detection of Pulmonary Colonization in Cystic Fibrosis Patients

Resource links provided by NLM:

Further study details as provided by Landon Pediatric Foundation:

Primary Outcome Measures:
  • Bacterial Identification [ Time Frame: six months ]
    Patient's provided breath samples and sputum for culture. Bacterial identification by indices was achieved

Enrollment: 24
Study Start Date: August 2009
Study Completion Date: December 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cystic Fibrosis Patients
Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not.
Other: Cystic Fibrosis patients
Healthy volunteers


Ages Eligible for Study:   1 Year to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients will be selected from Dr. Landon's primary care clinic.

Inclusion Criteria:

  • Clinical diagnosis of Cystic Fibrosis
  • Must be able to give breath and sputum samples

Exclusion Criteria:

  • Heavy smoker
  • Inability to regularly give breath and sputum samples
  • History of additional pulmonary disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01379040

United States, California
Pediatric Diagnostic Center
Ventura, California, United States, 93003
Sponsors and Collaborators
Landon Pediatric Foundation
  More Information


Responsible Party: Chris Landon, Principal Investigator, Landon Pediatric Foundation Identifier: NCT01379040     History of Changes
Other Study ID Numbers: CF1
Study First Received: June 21, 2011
Last Updated: August 12, 2014

Keywords provided by Landon Pediatric Foundation:
Cystic Fibrosis
Pseudomonas aeruginosa
Volatile Organic Compounds
Electronic nose
Gas Chromatography

Additional relevant MeSH terms:
Cystic Fibrosis
Pseudomonas Infections
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Gram-Negative Bacterial Infections
Bacterial Infections processed this record on May 25, 2017